Dogwood Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Stockholders' Equity (Details)

Stockholders' Equity (Details)								1 Months Ended		6 Months Ended
Stockholders' Equity (Details)	Apr. 21, 2026	Jan. 11, 2026 USD ($) $ / shares shares	Nov. 21, 2025 shares	Sep. 29, 2025 $ / shares shares	Apr. 07, 2025 shares	Mar. 12, 2025 USD ($) $ / shares shares	Oct. 17, 2024	Sep. 30, 2025 USD ($) shares	Oct. 31, 2024 shares	Jun. 30, 2026 USD ($) $ / shares shares	Jun. 30, 2025 USD ($)	Jun. 16, 2026 $ / shares shares	Jun. 15, 2026 shares	Mar. 11, 2026 shares	Jan. 15, 2026 $ / shares shares	Jan. 09, 2026 USD ($)	Dec. 31, 2025 USD ($) $ / shares shares	Nov. 28, 2025 USD ($)	Mar. 31, 2025 USD ($) shares	Oct. 07, 2024 $ / shares	Dec. 16, 2020 $ / shares shares
Stockholders' Equity
Common and preferred stock authorized (in shares)												200,000,000	45,000,000
Preferred stock authorized								2,000,000	2,000,000	5,000,000		5,000,000							2,000,000
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001		$ 0.0001
Temporary equity, shares authorized										2,104							2,104
Temporary equity, shares issued										0							0
Temporary equity, shares outstanding										0							0
Dividends payable \| $																			$ 1,770,767
Waiver of cash settlement and related repurchase rights for series A preferred stock								166
Waiver and conversion of preferred stock \| $								$ 5,500,000
Percentage of upfront payment to which holders are entitled									87.75%
Contingent value rights liability \| $										$ 0
Common stock authorized										195,000,000		195,000,000					43,000,000				195,000,000
Common stock, par value (in dollars per share) \| $ / shares										$ 0.0001		$ 0.0001					$ 0.0001				$ 0.0001
Net proceeds from issuance of common stock \| $										$ 11,397,459	$ 4,252,245
Deferred issuance costs \| $																$ 159,000	$ 158,956
Pre-funded Warrants
Stockholders' Equity
Warrants exercise price \| $ / shares										$ 0.0001					$ 0.0001
Warrants to purchase shares															2,047,089
Common Warrants
Stockholders' Equity
Offering price per share \| $ / shares															$ 3.28
Warrants exercise price \| $ / shares										$ 3.28
Warrants exercise period										5 years 6 months
Warrants to purchase shares														4,386,037	4,386,037
Number of warrants issued along with each common stock or warrant		1
PRIDCor Therapeutics, LLC License Agreement
Stockholders' Equity
Percentage of Series A financing receivable	10.00%
Percentage of financing receivable except Series A financing	9.00%
Revenue remaining performance obligation \| $										$ 0
PRIDCor Therapeutics, LLC License Agreement \| Maximum
Stockholders' Equity
Percentage of royalty on net sales	15.00%
Preferred Stock Excluding Series A and Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										4,997,254							1,997,254
Series A preferred stock
Stockholders' Equity
Preferred stock converted to common stock			10,000
Temporary equity, shares authorized									2,270	2,270							2,270
Temporary equity, shares issued										0							0
Temporary equity, shares outstanding										0							0
Preferred stock dividend rate percentage										5.00%
Preferred stock dividend payment period					180 days					180 days
PIK dividend, shares					55.345
Series A1 Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										285							285		285
Preferred stock, par value (in dollars per share) \| $ / shares						$ 0.0001
Preferred stock issued										0							0
Preferred stock outstanding										0							0
Preferred stock converted to common stock			10,000
Convertible Preferred Stock, Shares Issued upon Conversion						10,000
Series A-1 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										285							285
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001							$ 0.0001
Preferred stock issued										0							0
Preferred stock outstanding										0							0
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001
Series A2 Convertible Preferred stock
Stockholders' Equity
Preferred stock authorized								190.0572		190.0572							190.0572
Preferred stock issued										0							0
Preferred stock outstanding										0							0
Preferred stock converted to common stock			10,000
Series A-2 Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										190.0572							190.0572
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001							$ 0.0001
Preferred stock issued										0							0
Preferred stock outstanding										0							0
Common stock, par value (in dollars per share) \| $ / shares				0.0001
Series A Non-Voting Convertible Preferred Stock
Stockholders' Equity
Preferred stock authorized										166							166
Preferred stock, par value (in dollars per share) \| $ / shares										$ 0.0001							$ 0.0001
Preferred stock issued										0							0
Preferred stock outstanding										0							0
Common stock, par value (in dollars per share) \| $ / shares				0.0001
Series A Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001
Pharmagesic Holdings Inc.
Stockholders' Equity
Preferred stock, par value (in dollars per share) \| $ / shares																				$ 0.0001
Number of contingent value rights issuable for each common share							1
Contingent value rights agreement term							7 years
Percentage of upfront payment to which holders are entitled	87.75%						87.75%
Percentage of upfront payment entitled by entity	12.25%
Percentage ownership of outstanding rights that entitles holder to audit and enforcement							30.00%
Contingent value rights liability \| $										$ 0
Serpin Pharma \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid				191,017
Common stock, par value (in dollars per share) \| $ / shares				$ 0.0001
Serpin Pharma \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development
Stockholders' Equity
Total consideration paid				89.5939
Serpin Registration Rights Agreement \| Common Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid				191,017
Serpin Registration Rights Agreement \| Series A-2 Non-Voting Convertible Preferred Stock \| License for SP16 Development \| Serpin License Agreement
Stockholders' Equity
Total consideration paid				89.5939
At the market offering
Stockholders' Equity
Aggregate offering price \| $																		$ 8,558,712
January 2026 Offering
Stockholders' Equity
Offering price per share \| $ / shares		$ 2.85
Net proceeds from issuance of common stock \| $										$ 11,400,000
Offering price \| $ / shares		$ 2.8499
Gross proceeds \| $		$ 12,500,000
January 2026 Offering \| Pre-funded Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares		2,047,089
January 2026 Offering \| Common Warrants
Stockholders' Equity
Additional Gross Proceeds Receivable From Warrant Exercises \| $		$ 14,400,000
January 2026 Offering \| Common Warrants \| Maximum
Stockholders' Equity
Warrants to purchase shares		4,386,037
Registered Direct Offering
Stockholders' Equity
No of shares issued		2,338,948				578,950
Offering price per share \| $ / shares						$ 8.26
Gross proceeds from issuance of shares \| $						$ 4,780,000
Net proceeds from issuance of common stock \| $						$ 4,250,000
Private Offering \| Pre-funded Warrants
Stockholders' Equity
Warrants to purchase shares		2,047,089
Private Offering \| Common Warrants
Stockholders' Equity
Warrants to purchase shares		4,386,037